Global Next-Generation Oncology Solution 麻豆原创 Research Report 2024

Publication ID:

PB508245762

Publication Date:

August 28, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Next-generation oncology solutions refer to the advanced and innovative technologies, treatments, and approaches used to diagnose, treat, and manage cancer more effectively and efficiently. These solutions aim to improve patient outcomes, enhance precision medicine, and streamline oncology care by leveraging cutting-edge technologies and personalized treatment approaches.
The global Next-Generation Oncology Solution market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global market for next-generation oncology solutions has been witnessing substantial growth and innovation, driven by advancements in genomics, precision medicine, immunotherapy, and data analytics. These cutting-edge solutions are transforming cancer care by providing more personalized and effective treatment options for patients. The rising incidence of cancer worldwide is propelling the demand for advanced oncology solutions that can offer better treatment outcomes and improved patient care. Precision medicine approaches, which use genomic testing and targeted therapies, have gained prominence, driving the adoption of next-gen oncology solutions. The United States, in particular, is a major market for next-gen oncology solutions due to its robust research and development infrastructure, extensive clinical trials, and high cancer incidence. European countries have been early adopters of precision medicine and advanced oncology treatments, contributing to the growth of the market in this region. The Asia-Pacific region is witnessing significant growth in the oncology market, with countries like China, India, and Japan investing in healthcare infrastructure and research. The global market for next-generation oncology solutions is expected to continue its growth trajectory in the coming years. As technology continues to advance, precision medicine becomes more personalized, and immunotherapy gains further momentum, next-gen oncology solutions are likely to play an increasingly significant role in cancer care. Moreover, collaborations between pharmaceutical companies, research institutions, and healthcare providers are likely to drive innovation and accelerate the development and adoption of next-gen oncology treatments worldwide.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Oncology Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Oncology Solution.
Report Scope
The Next-Generation Oncology Solution market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next-Generation Oncology Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Oncology Solution companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Illumina
PerkinElmer
Thermo Fisher Scientific
Roche Holding
Agilent Technologies
Paige
GE Healthcare
Varian
Brainlab
Qiagen
Hologic
Pacific Biosciences
AstraZeneca
BGI Group
Segment by Type
Equipment (High-Intensity Focused Ultrasound, Advanced Forms of Radiation Therapy)
Software
Others
Segment by Application
Hospitals
Diagnostic Imaging Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Oncology Solution companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Next-Generation Oncology Solution 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Equipment (High-Intensity Focused Ultrasound, Advanced Forms of Radiation Therapy)
1.2.3 Software
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Next-Generation Oncology Solution 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Diagnostic Imaging Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Oncology Solution 麻豆原创 Perspective (2019-2030)
2.2 Next-Generation Oncology Solution Growth Trends by Region
2.2.1 Global Next-Generation Oncology Solution 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next-Generation Oncology Solution Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Next-Generation Oncology Solution Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Next-Generation Oncology Solution 麻豆原创 Dynamics
2.3.1 Next-Generation Oncology Solution Industry Trends
2.3.2 Next-Generation Oncology Solution 麻豆原创 Drivers
2.3.3 Next-Generation Oncology Solution 麻豆原创 Challenges
2.3.4 Next-Generation Oncology Solution 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Oncology Solution Players by Revenue
3.1.1 Global Top Next-Generation Oncology Solution Players by Revenue (2019-2024)
3.1.2 Global Next-Generation Oncology Solution Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Next-Generation Oncology Solution 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next-Generation Oncology Solution Revenue
3.4 Global Next-Generation Oncology Solution 麻豆原创 Concentration Ratio
3.4.1 Global Next-Generation Oncology Solution 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Oncology Solution Revenue in 2023
3.5 Next-Generation Oncology Solution Key Players Head office and Area Served
3.6 Key Players Next-Generation Oncology Solution Product Solution and Service
3.7 Date of Enter into Next-Generation Oncology Solution 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Oncology Solution Breakdown Data by Type
4.1 Global Next-Generation Oncology Solution Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Next-Generation Oncology Solution Forecasted 麻豆原创 Size by Type (2025-2030)
5 Next-Generation Oncology Solution Breakdown Data by Application
5.1 Global Next-Generation Oncology Solution Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Next-Generation Oncology Solution Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Next-Generation Oncology Solution 麻豆原创 Size (2019-2030)
6.2 North America Next-Generation Oncology Solution 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Next-Generation Oncology Solution 麻豆原创 Size by Country (2019-2024)
6.4 North America Next-Generation Oncology Solution 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Oncology Solution 麻豆原创 Size (2019-2030)
7.2 Europe Next-Generation Oncology Solution 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Next-Generation Oncology Solution 麻豆原创 Size by Country (2019-2024)
7.4 Europe Next-Generation Oncology Solution 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Oncology Solution 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Next-Generation Oncology Solution 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Next-Generation Oncology Solution 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Next-Generation Oncology Solution 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Oncology Solution 麻豆原创 Size (2019-2030)
9.2 Latin America Next-Generation Oncology Solution 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Next-Generation Oncology Solution 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Next-Generation Oncology Solution 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Oncology Solution 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Next-Generation Oncology Solution 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Next-Generation Oncology Solution 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Next-Generation Oncology Solution 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Next-Generation Oncology Solution Introduction
11.1.4 Illumina Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.1.5 Illumina Recent Development
11.2 PerkinElmer
11.2.1 PerkinElmer Company Detail
11.2.2 PerkinElmer Business Overview
11.2.3 PerkinElmer Next-Generation Oncology Solution Introduction
11.2.4 PerkinElmer Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.2.5 PerkinElmer Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Next-Generation Oncology Solution Introduction
11.3.4 Thermo Fisher Scientific Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Roche Holding
11.4.1 Roche Holding Company Detail
11.4.2 Roche Holding Business Overview
11.4.3 Roche Holding Next-Generation Oncology Solution Introduction
11.4.4 Roche Holding Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.4.5 Roche Holding Recent Development
11.5 Agilent Technologies
11.5.1 Agilent Technologies Company Detail
11.5.2 Agilent Technologies Business Overview
11.5.3 Agilent Technologies Next-Generation Oncology Solution Introduction
11.5.4 Agilent Technologies Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.5.5 Agilent Technologies Recent Development
11.6 Paige
11.6.1 Paige Company Detail
11.6.2 Paige Business Overview
11.6.3 Paige Next-Generation Oncology Solution Introduction
11.6.4 Paige Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.6.5 Paige Recent Development
11.7 GE Healthcare
11.7.1 GE Healthcare Company Detail
11.7.2 GE Healthcare Business Overview
11.7.3 GE Healthcare Next-Generation Oncology Solution Introduction
11.7.4 GE Healthcare Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.7.5 GE Healthcare Recent Development
11.8 Varian
11.8.1 Varian Company Detail
11.8.2 Varian Business Overview
11.8.3 Varian Next-Generation Oncology Solution Introduction
11.8.4 Varian Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.8.5 Varian Recent Development
11.9 Brainlab
11.9.1 Brainlab Company Detail
11.9.2 Brainlab Business Overview
11.9.3 Brainlab Next-Generation Oncology Solution Introduction
11.9.4 Brainlab Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.9.5 Brainlab Recent Development
11.10 Qiagen
11.10.1 Qiagen Company Detail
11.10.2 Qiagen Business Overview
11.10.3 Qiagen Next-Generation Oncology Solution Introduction
11.10.4 Qiagen Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.10.5 Qiagen Recent Development
11.11 Hologic
11.11.1 Hologic Company Detail
11.11.2 Hologic Business Overview
11.11.3 Hologic Next-Generation Oncology Solution Introduction
11.11.4 Hologic Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.11.5 Hologic Recent Development
11.12 Pacific Biosciences
11.12.1 Pacific Biosciences Company Detail
11.12.2 Pacific Biosciences Business Overview
11.12.3 Pacific Biosciences Next-Generation Oncology Solution Introduction
11.12.4 Pacific Biosciences Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.12.5 Pacific Biosciences Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Next-Generation Oncology Solution Introduction
11.13.4 AstraZeneca Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.13.5 AstraZeneca Recent Development
11.14 BGI Group
11.14.1 BGI Group Company Detail
11.14.2 BGI Group Business Overview
11.14.3 BGI Group Next-Generation Oncology Solution Introduction
11.14.4 BGI Group Revenue in Next-Generation Oncology Solution Business (2019-2024)
11.14.5 BGI Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Illumina
PerkinElmer
Thermo Fisher Scientific
Roche Holding
Agilent Technologies
Paige
GE Healthcare
Varian
Brainlab
Qiagen
Hologic
Pacific Biosciences
AstraZeneca
BGI Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.